Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.

Stephen Chia,Manuel Ruiz Borrego,Pamela Drullinsky,Dejan Juric,Thomas Bachelot,Hope S. Rugo,Eva Ciruelos,Florence Lerebours,Aleix Prat,Murat Akdere,Christina Arce,Ennan Gu,Nicholas C. Turner

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.

2021

Stephen Chia
Manuel Ruiz Borrego
Pamela Drullinsky
Dejan Juric
Thomas Bachelot
Hope S. Rugo
Eva Ciruelos
Florence Lerebours
Aleix Prat
Murat Akdere
Christina Arce
Ennan Gu
Nicholas C. Turner

1060Background: Mutations in PIK3CA (encoding PI3Kα) are present in 40% of HR+, HER2– ABC tumors and are associated with relative endocrine resistance and poor prognosis. ALP inhibits and degrades...

Keywords:

Medicine
in patient
advanced breast
poor prognosis
Cyclin-dependent kinase 4
Hormone receptor
Cancer research
Cancer
endocrine resistance
Human Epidermal Growth Factor Receptor 2

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations